← All trials
NCT03914404
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 26, 2016
- Primary completion
- Mar 30, 2016
- Completion date
- Jul 25, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chonbuk National UniversityLead sponsor
- Chonbuk National UniversityOverall official - principal investigator
- Chonbuk National UniversityReponsible party - principal investigator
- Gachon UniversityOverall official - principal investigator
- Daegu Catholic UniversityOverall official - principal investigator
- Inje UniversityOverall official - principal investigator
- Pusan National UniversityOverall official - principal investigator
- Dongguk UniversityOverall official - principal investigator
- Soon Chun Hyang UniversityOverall official - principal investigator
- Yonsei UniversityOverall official - principal investigator
- Catholic University of KoreaOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.